Endocrine Abstracts

Aim: To find if testosterone undecanoate (TUD) 1000 mg injection (NebidoR; Bayer-Schering) at 3 months has a negative effect on prostate.

Materials and method: i) PSA (ng/ml) registred before (T0) and after TUD at T1 (2 weeks) to T10 (7 years) (see Pisoschi, this Congress); ii) statistical analysis: t-test, simple correlation, and multiple regression.

Results: (A) Patients at onset: 143 men, 18–96 years, average: 60.38; median: 60. (B) Prostatic volume before TUD (cmc): average: 34.81; in evolution (see Pisoschi, this Congress). (C) Average PSA (no patients): before TUD=1.59 (143); at 1 year=1.69 (99); 2 years=1.4 (73); 3 years=1.85 (48); 4 years=2 (38); 5 years=1.86 (26); 6 years=1.51 (10); and 7 years=2.86 (6). (D) Statistical difference of average: nonsignificant for all the times from 2 weeks to 7 years. (E) Correlation between age and PSA was: i) significant before and after treatment till 2 years but nonsignificant for 3–7 years (PSA did not change as age after treatment). (F) Correlation between PSA and prostatic volume was significant, both before and after treatment (depending on group size); r before TUD=0.56, at 1 year=0.51, 2 years=0.55, 3 years=0.42, 4 years=0.11, 5 years=0.57, 6 years=−0.06, and 7 years=0.52. (G) Multiple regression test (r²=0.53–0.99, F=36.36–4906) shows that PSA level post testosterone does not depend on testosterone but on age, prostatic volume (before and after treatment), and PSA initial level (before testosterone administration); p<<0.001.

Conclusions: i) Testosterone undecanoate 1000 mg injectable i.m. at 3 months did not increase PSA level after 7 years administrations. ii) PSA level post testosterone was in fact dependent only on age, prostatic volume before treatment and PSA level before treatment.